Loxo Oncology Inc (NASDAQ:LOXO) has been assigned an average recommendation of “Buy” from the eleven analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $92.00.

Several equities research analysts have weighed in on the company. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. William Blair began coverage on Loxo Oncology in a research note on Tuesday, November 28th. They issued an “outperform” rating for the company. Citigroup decreased their price target on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. BidaskClub raised Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Finally, JMP Securities raised Loxo Oncology from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $77.18 to $95.00 in a research note on Tuesday, November 14th.

In related news, Director Avi Z. Naider sold 15,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the director now owns 141,118 shares of the company’s stock, valued at $14,111,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $75.00, for a total value of $37,500,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 1,628,396 shares of company stock valued at $125,989,430. Company insiders own 44.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Loxo Oncology by 20.6% during the second quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock valued at $128,534,000 after buying an additional 273,291 shares in the last quarter. Vanguard Group Inc. boosted its stake in Loxo Oncology by 24.7% during the second quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock valued at $73,351,000 after buying an additional 181,471 shares in the last quarter. Lord Abbett & CO. LLC boosted its stake in Loxo Oncology by 372.0% during the second quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock valued at $59,304,000 after buying an additional 582,862 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Loxo Oncology by 3.5% during the fourth quarter. Victory Capital Management Inc. now owns 450,947 shares of the biopharmaceutical company’s stock valued at $37,961,000 after buying an additional 15,155 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Loxo Oncology by 21.3% during the second quarter. Northern Trust Corp now owns 257,741 shares of the biopharmaceutical company’s stock valued at $20,668,000 after buying an additional 45,272 shares in the last quarter.

Shares of Loxo Oncology (NASDAQ LOXO) traded down $2.37 during midday trading on Friday, reaching $98.06. The company’s stock had a trading volume of 198,132 shares, compared to its average volume of 338,503. Loxo Oncology has a 1 year low of $38.94 and a 1 year high of $106.40. The firm has a market capitalization of $2,870.00, a price-to-earnings ratio of -16.88 and a beta of 2.56.

Loxo Oncology (NASDAQ:LOXO) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.38) by $0.26. research analysts anticipate that Loxo Oncology will post -5.91 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/02/03/loxo-oncology-inc-loxo-given-consensus-rating-of-buy-by-analysts.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.